Understanding the immune response in chronic Graft Versus Host Disease after stem cell transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the immune landscape associated with chronic Graft Versus Host Disease (cGVHD) following allogeneic stem cell transplantation. It aims to analyze the presence of specific immune cells, particularly T follicular helper (TFH) cells, and their interactions with B cells in cGVHD-affected tissues. By obtaining blood samples and biopsies from patients, the study seeks to identify tertiary lymphoid structures that may play a role in the disease's pathogenesis. The findings could lead to better understanding and treatment strategies for cGVHD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient \> 18 yo ;
* Having undergone an allogeneic stem cell tranplant ;
* 2 groups of patients will be eligible
* showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion

  * in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ;
  * in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ;
* Having read, understood and signed an informed consent of the study;
* With social security affiliation;

Exclusion Criteria:

* Patient below 18 yo or unable to give consent ;
* Systemic therapy using steroids over 15mg/d of Prednisone ; and/or the use of other systemic agent introduced in the last month ;
* Haemorrhagic risk of biopsy anticipated ;
* Absence of patient agreement for the study

Where it's running

• CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire
  Pessac, France Recruiting

Study contacts

• Study coordinator: Edouard FORCADE
• Email: edouard.forcade@chu-bordeaux.fr
• Phone: +33557656511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belumosudil vs Best Available Therapy for chronic graft-versus-host disease

  In people aged 12 and up with chronic graft-versus-host disease, the study tests belumosudil to see if it works better than the doctor’s choice of best available therapy after prior treatments have failed.

  Recruiting at 3 sites Phase 3 Sanofi · Amsterdam and 2 other locations · NCT07771439

• Mindfulness program to help with symptoms in chronic graft-versus-host disease

  A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07733141

• Madecassoside tablets plus standard therapy for sclered scl-cGVHD after allo-HSCT

  This study tests whether adding madecassoside tablets to standard therapy can help people with scleral chronic graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07606703

• Post-transplant dental cleaning to prevent chronic graft-versus-host disease

  This will try a dental cleaning about 28 days after an allogeneic stem cell transplant to see if it lowers the chance of chronic graft-versus-host disease in adult transplant recipients.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07535008

• Adrixetinib (Q702) for adults with active chronic graft-versus-host disease.

  This trial will test whether the oral drug Adrixetinib (Q702) is safe and helps adults with moderate or severe active chronic graft-versus-host disease who have not responded to standard treatments.

  Recruiting at 8 sites Phase 1 Qurient Co., Ltd. · Barcelona and 7 other locations · NCT07138196

• How whole versus crushed belumosudil tablets behave in people with chronic GVHD

  This will test whether taking belumosudil as whole tablets or crushed tablets suspended in water changes how the drug is absorbed in adults with chronic graft-versus-host disease.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07127926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.